IFP Advisors’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $71.3K | Sell |
950
-64
| -6% | -$5.05K | ﹤0.01% | 2052 |
|
|
2025
Q4 | $80.2K | Sell |
1,014
-56
| -5% | -$4.22K | ﹤0.01% | 1937 |
|
|
2025
Q3 | $70K | Buy |
1,070
+166
| +18% | +$8.11K | ﹤0.01% | 1897 |
|
|
2025
Q2 | $48.8K | Sell |
904
-246
| -21% | -$8.05K | ﹤0.01% | 2065 |
|
|
2025
Q1 | $42.4K | Hold |
1,150
| – | – | ﹤0.01% | 1967 |
|
|
2024
Q4 | $49.1K | Sell |
1,150
-76
| -6% | -$2.84K | ﹤0.01% | 1844 |
|
|
2024
Q3 | $49.1K | Buy |
1,226
+156
| +15% | +$7.26K | ﹤0.01% | 1744 |
|
|
2024
Q2 | $51K | Hold |
1,070
| – | – | ﹤0.01% | 1671 |
|
|
2024
Q1 | $46.4K | Hold |
1,070
| – | – | ﹤0.01% | 1621 |
|
|
2023
Q4 | $54.1K | Sell |
1,070
-71
| -6% | -$3.4K | ﹤0.01% | 1511 |
|
|
2023
Q3 | $51.8K | Sell |
1,141
-14
| -1% | -$578 | ﹤0.01% | 1536 |
|
|
2023
Q2 | $47.4K | Sell |
1,155
-814
| -41% | -$31.3K | ﹤0.01% | 1634 |
|
|
2023
Q1 | $91.8K | Sell |
1,969
-2,869
| -59% | -$108K | ﹤0.01% | 1293 |
|
|
2022
Q4 | $233K | Sell |
4,838
-951
| -16% | -$40K | 0.01% | 1282 |
|
|
2022
Q3 | $279K | Hold |
5,789
| – | – | 0.01% | 1233 |
|
|
2022
Q2 | $279K | Hold |
5,789
| – | – | 0.01% | 1114 |
|
|
2022
Q1 | $279K | Buy |
5,789
+3,116
| +117% | +$102K | 0.01% | 1114 |
|
|
2021
Q4 | $93K | Buy |
2,673
+953
| +55% | +$30K | ﹤0.01% | 1294 |
|
|
2021
Q3 | $66K | Buy |
1,720
+541
| +46% | +$20.4K | ﹤0.01% | 1471 |
|
|
2021
Q2 | $45K | Buy |
1,179
+881
| +296% | +$34.5K | ﹤0.01% | 1573 |
|
|
2021
Q1 | $13K | Sell |
298
-83
| -22% | -$4.63K | ﹤0.01% | 2026 |
|
|
2020
Q4 | $21K | Sell |
381
-518
| -58% | -$25.8K | ﹤0.01% | 1776 |
|
|
2020
Q3 | $43K | Sell |
899
-207
| -19% | -$11.5K | ﹤0.01% | 1346 |
|
|
2020
Q2 | $66K | Sell |
1,106
-8
| -0.7% | -$445 | 0.01% | 1088 |
|
|
2020
Q1 | $56K | Sell |
1,114
-415
| -27% | -$23.1K | 0.01% | 1063 |
|
|
2019
Q4 | $92K | Sell |
1,529
-1,703
| -53% | -$101K | 0.01% | 986 |
|
|
2019
Q3 | $192K | Buy |
+3,232
| New | +$211K | 0.01% | 781 |
|
|
2019
Q1 | $3K | Sell |
40
-889
| -96% | -$57.3K | ﹤0.01% | 2010 |
|
|
2018
Q4 | $48K | Sell |
929
-75
| -7% | -$3.83K | ﹤0.01% | 1638 |
|
|
2018
Q3 | $52K | Sell |
1,004
-1,468
| -59% | -$69K | ﹤0.01% | 1875 |
|
|
2018
Q2 | $103K | Sell |
2,472
-936
| -27% | -$41.5K | ﹤0.01% | 1463 |
|
|
2018
Q1 | $171K | Hold |
3,408
| – | – | 0.01% | 1060 |
|
|
2017
Q4 | $171K | Sell |
3,408
-1,759
| -34% | -$96.5K | 0.01% | 1066 |
|
|
2017
Q3 | $262K | Sell |
5,167
-513
| -9% | -$26.9K | 0.01% | 988 |
|
|
2017
Q2 | $289K | Sell |
5,680
-871
| -13% | -$40.6K | 0.01% | 922 |
|
|
2017
Q1 | $263K | Sell |
6,551
-2,483
| -27% | -$112K | 0.01% | 974 |
|
|
2016
Q4 | $432K | Buy |
9,034
+721
| +9% | +$28.5K | 0.02% | 682 |
|
|
2016
Q3 | $305K | Buy |
8,313
+1,207
| +17% | +$37.8K | 0.02% | 805 |
|
|
2016
Q2 | $165K | Buy |
7,106
+7,066
| +17,665% | +$228K | 0.01% | 1077 |
|
|
2016
Q1 | $3K | Sell |
40
-8,045
| -100% | -$327K | ﹤0.01% | 2007 |
|
|
2015
Q4 | $501K | Buy |
+8,085
| New | +$436K | 0.03% | 499 |
|
Other funds holding IONS
VPM
VCM
IFP Advisors's IONS Position: Q1 2026 in Review
IFP Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 6.3% in Q1 2026, selling an estimated $5.05K and leaving 950 shares worth $71.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2052.
IFP Advisors first reported a position in IONS in Q4 2015 and has held it in 41 quarters since. The position peaked at $501K in Q4 2015. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- IFP Advisors held 950 shares of Ionis Pharmaceuticals worth $71.3K as of Q1 2026.
- IFP Advisors sold 64 Ionis Pharmaceuticals shares in Q1 2026, an estimated $5.05K.
- Ionis Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #2052 holding.
- IFP Advisors first reported a position in Ionis Pharmaceuticals in Q4 2015 and has held it in 41 quarters since.
- IFP Advisors's Ionis Pharmaceuticals position peaked at $501K in Q4 2015.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.